Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer

Oncotarget

Volumn 7, Issue 6, 2016, Pages 7227-7240

  Feng, Wen ^a,b   Li, Yuan ^b   Shen, Lei ^b   Cai, Xu Wei ^a   Zhu, Zheng Fei ^b   Chang, Jian Hua ^b   Xiang, Jia Qing ^b   Zhang, Ya Wei ^b   Chen, Hai Quan ^b   Fu, Xiao Long ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Lymphocytic infiltration; Non small cell lung cancer; Prognosis; Survival; Tumor infiltrating lymphocytes

Indexed keywords

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; SQUAMOUS CELL LUNG CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

TUMOR MARKER;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84981288377     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6979     Document Type: Article

References (46)

1. Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C,De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E,Peters S. Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015; 26:1573-1588.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small-cell lung cancer, v.5.2015. http://www.nccn.org.
3. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, Diekemper R, Detterbeck FC, Arenberg DA. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143:314S-340S.
4. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350:379-392.
5. NSCLC Meta-analyses Collaborative Group, Arriagada R,Auperin A, Burdett S, Higgins JP, Johnson DH,Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375:1267-1277.
6. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2005; 2:CD002142.
7. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2006; 24:2998-3006.
8. Douillard JY, Rosell R, De LenaM, Riggi M, Hurteloup P,Mahe MA. Adjuvant Navelbine International Trialist Association. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys. 2008; 72:695-701.
9. Zou BW, Xu Y, Li T, Li W, Tang B, Zhou L, Li L, Liu Y,Zhu J, Huang M, Wang J, Ren L, Gong Y, et al. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in nonsmall-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys. 2010; 77:321-328.
10. Scotti V, Meattini I, Saieva C, Agresti B, de Luca Cardillo C, Bastiani P, Livi L, Mangoni M, Di Cataldo V, Marrazzo L, Rampini A, Cipressi S, Bruni A, et al. Post-operative radiotherapy in N2 non-small cell lung cancer: A retrospective analysis of 175 patients. Radiother Oncol. 2010; 96:84-88.
11. Dai HH, Hui ZG, Ji W, Liang J, Lu J, Ou G, Zhou Z, Feng Q, Xiao Z, Chen D, Zhang H, Yin W, He J, et al. Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: A retrospective study of 221 cases from a single institution. The Oncologist. 2011; 16:641-650.
12. Billiet C, Decaluwé H, Peeters S, Vansteenkiste J, Dooms C,Haustermans K, De Leyn P, De Ruysscher D. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. Radiother Oncol. 2014; 110:3-8.
13. Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN,Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol. 2015; 33:870-876.
14. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist. 2011; 16:672-681.
15. Feng W, Zhang Q, Fu XL, Cai XW, Zhu ZF, Yang HJ, Xiang JQ, Zhang YW, Chen HQ. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer. 2015; 15:348.
16. Feng W, Fu XL, Cai XW, Yang HJ, Wu KL, Fan M, Xiang JQ,Zhang YW, Chen HQ. Patterns of local-Regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design. Int J Radiat Oncol Biol Phys. 2014; 88:1100-1107.
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
18. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12:298-306.
19. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011; 8:711-719.
20. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011; 29:610-618.
21. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29:1093-1102.
22. Loi S, MacCallum P. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J Clin Oncol. 2014; 32:2936-2938.
23. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014; 232:199-209.
24. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B,Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P,Zinzindohoué F, Bruneval P, Cugnenc PH, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960-1964.
25. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y,Vignaud JM. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. 2002; 140:320-328.
26. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW.The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; 105:93-103.
27. Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK,Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013; 31:4252-4259.
28. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ,Wolff AC, Wood WC, Davidson NE, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol.2014; 32:2959-2967.
29. Jamieson NB, Mohamed M, Oien KA, Foulis AK, Dickson EJ,Imrie CW, Carter CR, McKay CJ, McMillan DC. The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2012; 19:3581-3590.
30. Bremnes RM, Al-Shibli K, Donnem T. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol. 2011; 6:824-833.
31. Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res. 2011; 17:5247-5256.
32. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM,Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res.2008; 14:5220-5227.
33. Lee TK, Horner RD, Silverman JF, Chen YH, Jenny C, Scarantino CW. Morphometric and morphologic evaluations in stage III non-small cell lung cancers: prognostic significance of quantitative assessment of infiltrating lymphoid cells. Cancer. 1989; 63:309-316.
34. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrì L,Daniele L, Oliaro A. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009; 87:365-371.
35. Mori M, Ohtani H, Naito Y, Sagawa M, Sato M, Fujimura S,Nagura H. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med. 2000; 191:113-118.
36. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favorable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006; 94:275-280.
37. Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. 2011; 167:207-210.
38. Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, Nason KS, Landreneau RJ, Luketich JD, Schuchert MJ. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011; 171:1-5.
39. Sasada T, Suekane S. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. Immunotherapy. 2011; 3:1235-1251.
40. Yoshino I, Yano T, Murata M, Miyamoto M, Ishida T, Sugimachi K, Kimura G, Nomoto K. Phenotypes of lymphocytes infiltrating non-small cell lung cancer tissues and its variation with histological types of cancer. Lung Cancer. 1993; 10:13-19.
41. Black CC, Turk MJ, Dragnev K, Rigas JR. Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung. 2013; 191:265-270.
42. Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol. 2013; 24:1170-1179.
43. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F,Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30:2046-2054.
44. Stinchcombe TE. Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol. 2014; 31:960.
45. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136:260-271.
46. Higgins KA, Chino JP, Berry M, Ready N, Boyd J, Yoo DS,Kelsey CR. Local failure in resected N1 lung cancer: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2012; 83:727-733.